Thanks Phase Two Ventures for your support, glad to have investors like you on our side.
Congratulations to Mason A. Chilmonczyk, PhD and the Andson Biotech team for closing their seed round. Phase Two is excited to be part of their journey in making Mass Spec workflows for biologics much easier. The DynaCHIP technology seamlessly integrates into existing mass spec workflows, significantly reducing sample prep times. https://lnkd.in/earvvJfv
The A-Alpha team is excited to participate in the Festival of Biologics Annual Meeting in San Diego next week! During the meeting, we will share our latest work on applying AlphaSeq and AlphaBind for immunocytokine engineering. In his talk, A-Alpha Co-Founder and CEO David Younger will delve into the applications of our platforms to engineer immunocytokine therapeutics using high-throughput experiments and machine learning. A-Alpha Principal Scientist Emily Engelhart will further present a poster on how our platforms enable the discovery and optimization of highly specific cis-targeting immunocytokines. If you’re attending, catch David’s talk and visit Emily’s poster to learn more. #biotech #immunocytokines #FestivalofBiologics
Thoughts on this? >> Ori Biotech, Cytiva separately unveil tech to accelerate cell therapy production >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #biotech #healthcare #productmarketing
#Biorepositories that collect, process, and store #biospecimens such as tissues, blood, DNA, and cells at subzero temperatures are crucial for advancing drug research, development, and manufacturing. These facilities ensure the integrity of essential biological materials, facilitating breakthroughs in understanding disease mechanisms and accelerating the development of #innovativetherapies. When establishing a #biorepository, #biotechnology and #pharmaceutical companies have two choices: They can either construct one from scratch, or they can purchase space in an existing facility. Our new article breaks down this topic, exploring the advantages of building vs. buying a biorepository. It also discusses how #CDMO partners like Thermo Fisher Scientific can provide storage support. You can read it here: http://spr.ly/6049jU6WZ
In the pursuit of precision medicine and biologics development, the need for efficient, reliable monoclonal cell lines has never been more critical. Discover how the DispenCell Single-Cell Dispenser and CloneSelect Imager FL not only speed up the isolation of single cells but also ensure their clonality and integrity through automated and high-throughput screening. This innovative approach significantly enhances the efficiency and yield of developing stable monoclonal cell lines, reducing labor and accelerating timelines. 👉 Read more about how we're setting new standards in cell line development. #CellLineDevelopment #MonoclonalityVerification #Biotechnology #SingleCellTechnology #LifeSciences #Innovation
This advanced-level course is designed to develop an understanding of complex concepts related to genomics, particularly CRISPR/Cas technology and its applications in drug discovery, therapeutics and much more. 🧫🧫🧫Enroll today https://lnkd.in/grHX4cq
2023 a year of challenge for many in the market; with less deals happening across Pharma, Biotech, Medtech and services coupled with economical hurdles for early and clinical stage organisations looking to raise. Despite this, the average deal value of Pharma almost tripled and Biotech nearly doubled comparative to 2022. Perhaps with a number of phIII trials failing and pipelines looking less secure than usual has led to such an increase? Less but more. Nice! #biotech #pharma #mergersandacquisitions
Scientist and Engineer | Executive MBA Candidate | Pharma and Biotech Content Creator | Science Liaison | Medical Writer
📈 𝐓𝐡𝐞 𝐌&𝐀 𝐢𝐧 𝐥𝐢𝐟𝐞 𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬 Dealmaking in the life sciences sector revived in 2023, focusing on M&A, resulting in a jump of 23% in the value of transactions compared to previous years. Pharma companies were pursuing growth, and medtech companies were chasing profitability. Pharmaceutical companies are targeting pre-commercial biotech assets to expand their R&D and secure a leading position in emerging fields like cell and gene therapy and biologics. Medtech, on the other hand, leans towards digital transformation, expanding their ecosystems to improve patient outcomes through technology-driven solutions, beyond their core physical products. Source and credits: McKinsey & Company More info: https://lnkd.in/dxXhNJcb #pharma #biotech #medtech #womeninbusiness #drjojo
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Ori Biotech, Cytiva separately unveil tech to accelerate cell therapy production >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #productmarketing #biotech
Watch as Mike Ward and Matthew Arnold discuss trends to watch in life sciences and healthcare, including the increase of high-valued partnering deals centered on preclinical assets in the pharma industry. They note, "The biotech sector has returned to pre-pandemic fundraising and deal-making norms. During the pandemic, biotech and biopharma were the month's flavor because of the efforts they've been making to take on that challenge. In contrast, we're now in a sort of hangover period. Still, there are some green shoots." Pharmas will now have to replenish their portfolios with innovative medicines and new technologies like ADCs and gene editing. Read more: https://ow.ly/me3150QiMWz #biotech #pharma #partnership #trendstowatch
Interesting and extensive view of the latest trends in Biotech R&D areas. Neil Torbett and Hanjo Kim are some of the great visionaries sharing his views on this article by Labiotech.eu
Did you spot Dr Neil Torbett in Labiotech.eu’s recent article on 2024 biotech trends? Neil shared his thoughts on how the next year will be transformative for the design and development of degrader therapeutics. Read more: https://rb.gy/4x9wwy #DrugDiscovery #TPD #MolecularGlues
𝗢𝗹𝗶𝗴𝗼𝗻𝘂𝗰𝗹𝗲𝗼𝘁𝗶𝗱𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗮𝗿𝗲 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘀𝗶𝗻𝗴 𝗴𝗲𝗻𝗲 𝗮𝗻𝗱 𝗱𝗶𝘀𝗲𝗮𝘀𝗲-𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀, 𝗯𝘂𝘁 𝗲𝗻𝘀𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗲𝗶𝗿 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗮𝗻𝗱 𝘀𝗮𝗳𝗲𝘁𝘆 𝗶𝘀 𝗰𝗿𝘂𝗰𝗶𝗮𝗹. 👨⚕️🧬🧪 Check out our latest article where we introduce a cutting-edge workflow for impurity analysis using the LCMS-9050 and LabSolutions Insight Biologics. 🌟✨ This workflow is lightning-fast, ultra-sensitive, and remarkably accurate when it comes to identifying impurities in these drugs. 💡🔬 Read more about this groundbreaking technology here: https://lnkd.in/d9VaCDqy and don't hesitate to share your thoughts and questions below! 💭💬 #Shimadzu #LCMS #ImpurityAnalysis #OligonucleotideTherapeutics #QualityAndSafety #Innovation #BioTech
